Objective To evaluate the impact of World Health Organization(WHO)-recommended multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment regimen on China's effort of ending TB epidemic if it is applied in 2025.
Methods Based on the epidemiological data of TB in China from 2015 to 2021 and previous research data, the impact of WHO-recommended regimen on the spread, incidence, cure and death of TB and MDR/RR-TB in China was predicted by using infectious disease dynamics model.
Results If the regimen is applied in 2025, another 116,100 MDR/RR-TB patients will be successfully cured, resulting in decreases of 58 200 deaths, 75 700 cases and 12 500 cases from latent infections of MDR/RR-TB in the next decade (2025−2035).
Conclusion Based on the analysis on its efficacy in the treatment of MDR/RR-TB, the application of WHO-recommended regimen has public health significance in the prevention and control of MDR/RR-TB in China.
Home
DownLoad: